E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Severe Acute Alcoholic Hepatitis (sAAH) |
|
E.1.1.1 | Medical condition in easily understood language |
Severe Acute Alcoholic Hepatitis (sAAH) |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Metabolic Phenomena [G03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10019755 |
E.1.2 | Term | Hepatitis chronic active |
E.1.2 | System Organ Class | 10019805 - Hepatobiliary disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to evaluate safety and efficacy of ELAD with respect to overall survival (OS) at Study Day 91 in subjects with a clinical diagnosis of severe acute alcoholic hepatitis (sAAH) who have failed steroid therapy. Folow-up protocol VTI-210E will provide additonal survival data up to a maximum of 5 yeas that will be included, as available, through VTI-210 study termination (after all enrolled subjects complete study day 91, are lost to follow-up or withdraw consent, or die before the study day). The primary objective will be assessed using a Kaplan-Meier survival analysis of the intent-to-treat (ITT) population utilizing a log-rank test to evaluate the null hypthesis of equality of survival curves |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives are to evaluate the proportion of survivors (ITT population) at Study Days 28 and 91 using the chi-square test. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects must meet ALL inclusion criteria to be eligible for the study:
1. Age ≥ 18;
2. Total bilirubin ≥ 8 mg/dL;
3. Medical history of alcohol abuse with evidence of causal and temporal (<6weeks) relationship to the use of alcohol and the onset of symptoms;
4. Maddrey score of ≥ 32;
5. A clinical diagnosis of severe acute alcoholic hepatitis (sAAH) defined asmeeting two or more of the following:
a. Hepatomegaly
b. AST > ALT
c. Ascites
d. Leukocytosis (WBC count above lab normal at site);
6. Subject must have either:
a. a liver biopsy that, in the investigator's opinion, confirms a diagnosis of sAAH (stratum A)
OR
b. in the investigator's opinion, a liver biopsy is not justified due to the risk versus the diagnosis value, and no confirmatory liver biopsy is available, in which case the clinical diagnosis is sufficient (stratum B);
7. Subject must have failed steroid therapy according to the Lille protocol (Lille score >0.45) after completing 7 days of steroids;
8. Subject must be eligible for Standard of Care treatment as defined in the protocol;
9. Subject or legally authorized representative must provide Informed Consent for all phases of the study (Treatment, and 5-year Follow-Up Registry); |
|
E.4 | Principal exclusion criteria |
Subjects must NOT meet any of the following exclusion criteria:
1. Platelet count < 50,000/mm3;
2. International Normalization Ratio (INR) > 3.0;
3. MELD score > 35;
4. Evidence of infection unresponsive to antibiotics (e.g. increased tissue involvement relative to initial diagnosis, clinical worsening of symptom, etc.) indicated by any of the following:
a. Presence of sepsis or septic shock; OR
b. Positive blood cultures (bacteremia, fungemia) within 72 hours prior to Randomization; OR
c. Presence of spontaneous bacterial peritonitis during the 2 days prior to Randomization; OR
d. Clinical and radiological signs of pneumonia;
5. Evidence of more than one steroid regimen during this episode of liver failure;
6. Hospital admission for any other episodes of liver decompensation within the past 2 months;
7. Evidence of hemodynamic instability as defined by the following:
a. Systolic blood pressure < 90 mmHg with evidence of diminished perfusion unresponsive to fluid resuscitation and/or low-dose pressor support; OR
b. Mean arterial pressure (MAP) < 60 mmHg with evidence of diminished perfusion unresponsive to fluid resuscitation and/or low-dose pressor support; OR
c. Requirement for escalating doses of vasopressor support prior to Screening; OR
d. Subject at maximum vasopressor dose at Screening or Randomization (low doses are allowed);
low dose vasopressor doses are defined as:
• Dobutamine: Low doses: 2.5 to 5.0 mcg/kg/min
• Dopamine: Low doses: 0.5 to 2 mcg/kg/min
• Norepinephrine: Low doses: 0.01 to 0.02 mcg/kg/min
• Phenylephrine: Low doses: 0.05 to 1 mcg/kg/min
• Vasopressin: Low doses: 0.01 to 0.02 U/min
8. Evidence of active bleeding or of major hemorrhage defined as requiring ≥ 2 units packed red blood cells to maintain a stable hemoglobin occurring within 48 hours of Screening;
9. Evidence of occlusive portal vein thrombosis impairing hepatopetal flow, or evidence of bile duct obstruction;
10. Evidence by physical exam, history, or laboratory evaluation of significant concomitant disease with expected life expectancy of less than 3 months, including but not limited to:
a. Severe acute or chronic cardiovascular, central nervous system, or pulmonary disease;
b. Cancer that has metastasized or has not yet been treated;
11. Clinical evidence of liver size reduction due to cirrhosis [liver size of the craniocaudal diameter
(sagittal view) < 10 cm when measured on the mid-clavicular line (or equivalent measurement) by ultrasound, or liver volume < 750 cc as determined by CT], unless Investigator interpretation of the clinical evidence indicates liver size of < 10 cm or volume < 750cc is not considered reduced for the individual subject;
12. Chronic end-stage renal disease requiring chronic hemodialysis for more than 8 weeks (not classified as hepatorenal syndrome);
13. Uncontrolled seizures;
14. Positive serologies for viral hepatitis B (HBsAg) or hepatitis C indicating acute/chronic infection or a positive viral load for either hepatitis B or C;
15. Pregnancy as determined by β-human chorionic gonadotropin (HCG) results;
16. Participation in another investigational drug, biologic, or device study within one month of
enrollment, except for observational studies (the observational study setting should not affect the safety and/or efficacy of the VTI-210 clinical trial);
17. Currently listed or scheduled for liver transplant during the 90-day study period;
18. Previous liver transplant;
19. Previous participation in an ELAD clinical trial as either ELAD or Control subject;
20. Has a Do Not Resuscitate or a Do Not Intubate (DNR/DNI) directive (or local equivalent) or any other Advanced Directive limiting Standard of Care in place;
21. Refusal to participate in the VTI-210E follow-up study;
22. Is unable to provide an address for follow-up home visits.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Overall survival (OS) will be assessed using a Kaplan-Meier survival analysis of the ITT population utilizing a log-rank test to evaluate the null hypothesis of equality of survival curves, with follow-up Protocol VTI-210E providing additional survival data up to a maximum of 5 years that will be included, as available, through VTI-210 study termination (after all enrolled subjects either complete Study Day 91, are lost to follow up or withdraw consent, or die before that Study Day). The model will be stratified by whether or not the clinical diagnosis of sAAH was confirmed with a liver biopsy. Model-based estimates and confidence limits will be calculated for median survival by treatment group and hazard rates along with the hazard ratio and its confidence limits. This analysis will also be carried out on the per-protocol (PP) population as a sensitivity analysis. In addition, a similar sensitivity analysis for Overall Survival will be carried out using only survival data captured up to the End of Study Day 91. Two-tailed alpha for the log-rank test will be set at 0.05. The statistical analysis plan will outline the methods used to define the ITT and PP populations and to account for missing data in this and all other analyses. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After all enrolled subjects either complete Study Day 91, are lost to follow up or withdraw consent, or die before that Study Day
|
|
E.5.2 | Secondary end point(s) |
A chi-square test will be used to evaluate the proportion of subjects who survived at End of Study Day 28 and End of Study Day 91 based on the ITT population. These analyses will also be performed using a Cochran-Mantel-
Haenszel (CMH) test stratified by whether or not the clinical diagnosis of sAAH was confirmed with a liver biopsy to compare the proportion of subjects who have survived at End of Study Day 28 and End of Study Day 91 respectively.
CMH analyses are considered sensitivity analyses to help evaluate consistency across subgroups based on the stratification factor. Two-tailed alpha will be set at 0.05 for each test. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The secondary objectives are to evaluate the proportion of survivors at Study Days 28 and 91. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Standard of care treatment for AAH (as defined in the protocol) |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 25 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Germany |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 0 |